目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 28)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.3 MARKETS COVERED
FIGURE 1 COMPANION DIAGNOSTICS MARKET SEGMENTATION
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 32)
2.1 RESEARCH DATA
FIGURE 2 COMPANION DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 COMPANION DIAGNOSTICS MARKET: BOTTOM-UP APPROACH
2.2.1.2 Approach 2: Presentations of companies and primary interviews
2.2.1.3 Growth forecast (2021-2026)
2.2.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.2.2 TOP-DOWN APPROACH
FIGURE 6 COMPANION DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
2.6 LIMITATIONS
2.7 RISK ASSESSMENT
2.7.1 RISK ASSESSMENT: COMPANION DIAGNOSTICS MARKET
2.8 GROWTH RATE ASSUMPTIONS
2.9 COVID-19 HEALTH ASSESSMENT
2.10 COVID-19 ECONOMIC ASSESSMENT
2.11 ASSESSMENT OF IMPACT OF COVID-19 ON ECONOMIC SCENARIO
FIGURE 8 CRITERIA IMPACTING GLOBAL ECONOMY
FIGURE 9 RECOVERY SCENARIO OF GLOBAL ECONOMY
2.12 ASSESSMENT OF IMPACT OF COVID-19 ON ECONOMIC SCENARIO IN COMPANION DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY (Page No. - 48)
FIGURE 10 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
FIGURE 11 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 12 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 13 COMPANION DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 14 COMPANION DIAGNOSTICS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 52)
4.1 COMPANION DIAGNOSTICS MARKET OVERVIEW
FIGURE 15 GROWING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
4.2 COMPANION DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026
FIGURE 16 ASSAYS, KITS & REAGENTS SEGMENT TO DOMINATE MARKET IN 2026
4.3 COMPANION DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026
FIGURE 17 POLYMERASE CHAN REACTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
4.4 COMPANION DIAGNOSTICS MARKET SHARE, BY INDICATION, 2021 VS. 2026
FIGURE 18 CANCER SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.5 COMPANION DIAGNOSTICS MARKET SHARE, BY END USER, 2021 VS. 2026
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO LEAD MARKET IN 2026
4.6 COMPANION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN COMPANION DIAGNOSTICS MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 56)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Advantages of companion diagnostics
5.2.1.1.1 Growing need for targeted therapy
5.2.1.1.2 Rising importance of personalized medicine
FIGURE 22 GLOBAL LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008-2020
FIGURE 23 GROWTH IN US FDA PERSONALIZED MEDICINE APPROVAL RATE, 2015-2020
5.2.1.1.3 Increasing global incidence of cancer
FIGURE 24 GLOBAL CANCER INCIDENCE, 2008-2030
5.2.1.1.4 Growing application areas of companion diagnostics
5.2.2 RESTRAINTS
5.2.2.1 High capital investment and low cost-benefit ratio
5.2.2.2 Expensive companion diagnostic tests
5.2.2.3 Uncertain reimbursement scenario in different regions
TABLE 1 COMPANION DIAGNOSTICS REIMBURSEMENT SCENARIO WORLDWIDE
5.2.2.4 High cost of immunotherapy treatment
TABLE 2 COST OF KEYTRUDA, BY REGION (2018)
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing demand for next-generation sequencing
TABLE 3 PARTNERSHIPS & COLLABORATIONS FOR DEVELOPING NGS-BASED COMPANION DIAGNOSTIC TESTS
5.2.3.2 Growing significance of companion diagnostics in drug development
5.2.3.3 Higher number of clinical trials
TABLE 4 LIST OF CLINICAL TRIALS FOR COMPANION DIAGNOSTICS
5.2.4 CHALLENGES
5.2.4.1 Shortage of trained professionals
5.2.4.2 Lack of awareness of companion diagnostics testing
5.3 IMPACT OF COVID-19 ON COMPANION DIAGNOSTICS MARKET
5.4 PESSIMISTIC, OPTIMISTIC, AND REALISTIC SCENARIOS
5.4.1 COMPANION DIAGNOSTICS MARKET
FIGURE 25 PESSIMISTIC SCENARIO
FIGURE 26 OPTIMISTIC SCENARIO
FIGURE 27 REALISTIC SCENARIO
5.5 PRICING ANALYSIS
TABLE 5 PRICE OF COMPANION DIAGNOSTICS PRODUCT & SERVICE (2021)
5.6 PATENT ANALYSIS
FIGURE 28 PATENT ANALYSIS OF COMPANION DIAGNOSTICS MARKET
5.7 TRADE ANALYSIS
5.7.1 TRADE ANALYSIS FOR COMPANION DIAGNOSTICS
TABLE 6 IMPORT DATA FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2016-2020 (USD MILLION)
TABLE 7 EXPORT DATA FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2016-2020 (USD MILLION)
5.8 VALUE CHAIN ANALYSIS
FIGURE 29 MAJOR VALUE IS ADDED DURING MANUFACTURING & ASSEMBLY PHASE
5.9 SUPPLY CHAIN ANALYSIS
FIGURE 30 COMPANION DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
5.10 ECOSYSTEM ANALYSIS OF COMPANION DIAGNOSTICS MARKET
FIGURE 31 COMPANION DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
5.10.1 ROLE IN ECOSYSTEM
5.11 PORTER’S FIVE FORCES ANALYSIS
TABLE 8 COMPANION DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF BUYERS
5.11.4 BARGAINING POWER OF SUPPLIERS
5.11.5 DEGREE OF COMPETITION
5.12 REGULATORY LANDSCAPE
5.12.1 NORTH AMERICA
5.12.1.1 US
5.12.1.2 Canada
5.12.2 EUROPE
5.12.3 ASIA PACIFIC
5.12.3.1 China
5.12.3.2 Japan
5.12.3.3 India
5.12.4 LATIN AMERICA
5.12.4.1 Brazil
5.12.4.2 Mexico
5.12.5 MIDDLE EAST
5.13 TECHNOLOGY ANALYSIS
5.14 PESTLE ANALYSIS
5.15 TRENDS/DISRUPTIONS IMPACTING THE BUSINESS OF CUSTOMERS
5.15.1 REVENUE SOURCES ARE SHIFTING TOWARDS TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-19 PANDEMIC
5.15.2 REVENUE SHIFT FOR COMPANION DIAGNOSTICS MARKET

6 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 82)
6.1 INTRODUCTION
TABLE 9 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 10 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
6.2 ASSAYS, KITS & REAGENTS
6.2.1 INCREASING VOLUME OF CDX TESTS PERFORMED IN LABORATORIES TO SUPPORT ADOPTION OF ASSAYS & KITS
TABLE 11 KEY PRODUCTS IN ASSAYS AND KITS, BY COMPANY
TABLE 12 COMPANION DIAGNOSTIC ASSAYS, KITS& REAGENTS MARKET, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 13 COMPANION DIAGNOSTIC ASSAYS, KITS& REAGENTS MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
6.3 SOFTWARE & SERVICES
6.3.1 NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTICS TESTS TO SUPPORT MARKET GROWTH
TABLE 14 KEY PRODUCTS IN SOFTWARE & SERVICES, BY COMPANY
TABLE 15 COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 16 COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY COUNTRY, 2021-2026 (USD MILLION)

7 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 90)
7.1 INTRODUCTION
TABLE 17 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 18 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
7.2 POLYMERASE CHAIN REACTION (PCR)
7.2.1 GROWING APPLICATIONS IN PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE GROWTH
TABLE 19 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR DETECTION OF RAS/BRAF MUTATION
TABLE 20 MAJOR PCR TESTS/KITS AVAILABLE
TABLE 21 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 22 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2021-2026 (USD MILLION)
7.3 NEXT-GENERATION SEQUENCING
7.3.1 EXPECTED TO RECORD HIGHEST CAGR DURING FORECAST PERIOD
TABLE 23 MAJOR NGS TESTS/KITS AVAILABLE
TABLE 24 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 25 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2021-2026 (USD MILLION)
7.4 IN SITU HYBRIDIZATION
7.4.1 INCREASING DEMAND IN SMALL-TUMOR DIAGNOSTICS TO DRIVE GROWTH
TABLE 26 MAJOR ISH TESTS/KITS AVAILABLE
TABLE 27 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 28 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2021-2026 (USD MILLION)
7.5 IMMUNOHISTOCHEMISTRY (IHC)
7.5.1 INCREASING DEMAND FOR USER-FRIENDLY AND COST-EFFECTIVE TECHNOLOGIES TO SUPPORT GROWTH
TABLE 29 MAJOR IHC TESTS/KITS AVAILABLE
TABLE 30 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 31 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021-2026 (USD MILLION)
7.6 OTHER TECHNOLOGIES
TABLE 32 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 33 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021-2026 (USD MILLION)

8 COMPANION DIAGNOSTICS MARKET, BY INDICATION (Page No. - 106)
8.1 INTRODUCTION
TABLE 34 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 35 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
8.2 CANCER
TABLE 36 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2020 (USD MILLION)
TABLE 37 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2021-2026 (USD MILLION)
TABLE 38 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 39 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2021-2026 (USD MILLION)
8.2.1 LUNG CANCER
8.2.1.1 Growing demand for effective therapeutic drugs to increase CDX adoption
FIGURE 32 GLOBAL LUNG CANCER INCIDENCE, 2012-2030
TABLE 40 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 41 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2021-2026 (USD MILLION)
8.2.2 BREAST CANCER
8.2.2.1 Wide prevalence of breast cancer among women contributes to large size of segment
TABLE 42 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2030
TABLE 43 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 44 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2021-2026 (USD MILLION)
8.2.3 BLOOD CANCER
8.2.3.1 Increasing incidence of disease to boost market
TABLE 45 BLOOD CANCER INCIDENCE, BY REGION, 2020 VS. 2030
TABLE 46 COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 47 COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2021-2026 (USD MILLION)
8.2.4 COLORECTAL CANCER
8.2.4.1 Rising need for molecular profiling of primary tumors to drive segment growth
TABLE 48 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 49 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2021-2026 (USD MILLION)
8.2.5 OTHER CANCERS
TABLE 50 COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 51 COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2021-2026 (USD MILLION)
8.3 INFECTIOUS DISEASES
8.3.1 INCREASING AWARENESS OF TARGETED THERAPIES TO PROPEL SEGMENT GROWTH
TABLE 52 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 53 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DIESEASES, BY COUNTRY, 2021-2026 (USD MILLION)
8.4 CARDIOVASCULAR DISEASES
8.4.1 RISING DEMAND FOR TARGETED THERAPIES TO DRIVE SEGMENT GROWTH
TABLE 54 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 55 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2026 (USD MILLION)
8.5 NEUROLOGICAL DISEASES
8.5.1 GROWING NUMBER OF ADVANCED TECHNOLOGIES TO BOOST ADOPTION OF COMPANION DIAGNOSTICS
TABLE 56 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 57 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021-2026 (USD MILLION)
8.6 OTHER INDICATIONS
TABLE 58 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 59 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2026 (USD MILLION)

9 COMPANION DIAGNOSTICS MARKET, BY END USER (Page No. - 132)
9.1 INTRODUCTION
TABLE 60 COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 61 COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 INCREASING USE OF CDX IN PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DRIVE MARKET GROWTH
TABLE 62 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 63 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2026 (USD MILLION)
9.3 REFERENCE LABORATORIES
9.3.1 RISING DEMAND FOR TARGETED THERAPIES TO DRIVE GROWTH
TABLE 64 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 65 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2021-2026 (USD MILLION)
9.4 CONTRACT RESEARCH ORGANIZATIONS
9.4.1 SIGNIFICANT DEMAND FOR COMPANION DIAGNOSTIC PRODUCTS FOR USE IN THERAPY-RELATED CLINICAL TRIALS
TABLE 66 COMPANION DIAGNOSTICS MARKET FOR CRO, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 67 COMPANION DIAGNOSTICS MARKET FOR CRO BY COUNTRY, 2021-2026 (USD MILLION)
9.5 OTHER END USERS
TABLE 68 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 69 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2026 (USD MILLION)

10 COMPANION DIAGNOSTICS MARKET, BY REGION (Page No. - 142)
10.1 INTRODUCTION
TABLE 70 COMPANION DIAGNOSTICS MARKET, BY REGION, 2017-2020 (USD MILLION)
TABLE 71 COMPANION DIAGNOSTICS MARKET, BY REGION, 2021-2026 (USD MILLION)
10.2 NORTH AMERICA
TABLE 72 NUMBER OF NEW CANCER CASES IN NORTH AMERICA IN 2020, BY TYPE OF CANCER
FIGURE 33 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012-2035
FIGURE 34 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT
TABLE 73 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 74 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 75 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 76 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 77 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 78 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 79 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 80 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 81 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 82 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 83 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 84 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.2.1 US
10.2.1.1 Increasing use of companion diagnostics for cancer treatment boosts market
TABLE 85 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 86 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 87 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 88 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 89 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 90 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 91 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 92 US: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 93 US: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 94 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 95 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing government initiatives expected to drive market
TABLE 96 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 97 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 98 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 99 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 100 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 101 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 102 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 103 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 104 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 105 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 106 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.3 EUROPE
FIGURE 35 EUROPE: CANCER INCIDENCE & MORTALITY, 2012-2035
TABLE 107 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 108 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 109 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 110 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 111 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 112 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 113 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 114 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 115 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 116 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 117 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 118 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Favorable government policies to drive market
TABLE 119 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 120 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 121 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 122 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 123 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 124 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 125 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 126 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 127 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 128 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 129 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.3.2 UK
10.3.2.1 Growing life science industry and increasing focus on research to propel market
TABLE 130 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 131 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 132 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 133 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 134 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 135 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 136 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 137 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 138 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 139 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.3.3 SWITZERLAND
10.3.3.1 Strong research-oriented pharma industry supports market growth
TABLE 140 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 141 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 142 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 143 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 144 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 145 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 146 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 147 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 148 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 149 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Increasing government funding for research to support market growth
TABLE 150 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 151 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 152 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 153 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 154 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 155 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 156 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 157 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 158 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 159 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Growing demand for better and more powerful therapeutics
TABLE 160 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 161 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 162 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 163 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 164 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 165 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 166 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 167 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 168 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 169 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Increasing focus on advancement of personalized medicine to drive market growth
TABLE 170 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 171 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 172 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 173 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 174 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 175 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 176 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 177 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 178 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 179 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 180 ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 181 ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 182 ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 183 ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 184 ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 185 ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 186 ROE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 187 ROE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 188 ROE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 189 ROE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 36 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012-2035
FIGURE 37 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT
TABLE 190 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 191 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 192 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 193 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 194 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 195 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 196 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 197 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 198 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 199 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 200 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 201 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Growing public access to advanced healthcare facilities to drive market
TABLE 202 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 203 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 204 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 205 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 206 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 207 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 208 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 209 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 210 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 211 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Research initiatives supporting market growth
TABLE 212 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 213 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 214 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 215 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 216 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 217 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 218 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 219 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 220 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 221 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 222 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Increased demand for early cancer diagnosis to support market growth
TABLE 223 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 224 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 225 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 226 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 227 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 228 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 229 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 230 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 231 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 232 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 233 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.4.4 AUSTRALIA
10.4.4.1 Initiatives to enhance healthcare access and infrastructure for aging population to drive market
TABLE 234 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 235 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 236 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 237 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 238 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 239 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 240 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 241 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 242 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 243 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.4.5 REST OF ASIA PACIFIC
TABLE 244 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 245 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 246 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 247 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 248 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 249 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 250 ROAPAC: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 251 ROAPAC: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 252 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 253 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.5 LATIN AMERICA
TABLE 254 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 255 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 256 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 257 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 258 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 259 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 260 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 261 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 262 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 263 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 264 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 265 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.5.1 BRAZIL
10.5.1.1 Increasing incidence of lifestyle diseases drives market
TABLE 266 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 267 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 268 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 269 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 270 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 271 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 272 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 273 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 274 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 275 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.5.2 MEXICO
10.5.2.1 Growing medical tourism to fuel demand for companion diagnostics
TABLE 276 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 277 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 278 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 279 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 280 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 281 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 282 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 283 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 284 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 285 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.5.3 REST OF LATIN AMERICA
TABLE 286 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 287 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 288 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 289 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 290 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 291 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 292 ROLATAM: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 293 ROLATAM: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 294 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 295 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET GROWTH
TABLE 296 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
TABLE 297 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 298 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
TABLE 299 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 300 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
TABLE 301 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
TABLE 302 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
TABLE 303 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
TABLE 304 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 305 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 270)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN COMPANION DIAGNOSTICS MARKET
TABLE 306 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANION DIAGNOSTICS MANUFACTURING COMPANIES
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN COMPANION DIAGNOSTICS MARKET (2015-2020)
11.4 MARKET SHARE ANALYSIS
FIGURE 39 COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2020)
TABLE 307 COMPANION DIAGNOSTICSMARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION QUADRANT
11.5.1 LIST OF EVALUATED VENDORS
11.5.2 STARS
11.5.3 EMERGING LEADERS
11.5.4 PERVASIVE PLAYERS
11.5.5 PARTICIPANTS
FIGURE 40 COMPANION DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
11.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 41 COMPANION DIAGNOSTICSMARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020
11.7 COMPETITIVE BENCHMARKING
11.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
FIGURE 42 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN COMPANION DIAGNOSTICSMARKET
TABLE 308 PRODUCT FOOTPRINT OF COMPANIES
TABLE 309 REGIONAL FOOTPRINT OF COMPANIES
11.8 COMPETITIVE SCENARIO
11.8.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
TABLE 310 KEY PRODUCT LAUNCHES
11.8.2 DEALS
TABLE 311 KEY DEALS

12 COMPANY PROFILES (Page No. - 281)
(Business overview, Products offered, Recent developments & MnM View)*
12.1 KEY PLAYERS
12.1.1 F. HOFFMANN-LA ROCHE AG
TABLE 312 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
FIGURE 43 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020)
12.1.2 AGILENT TECHNOLOGIES, INC.
TABLE 313 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 44 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
12.1.3 QIAGEN
TABLE 314 QIAGEN: BUSINESS OVERVIEW
FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2020)
12.1.4 THERMO FISHER SCIENTIFIC, INC.
TABLE 315 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 46 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
12.1.5 ABBOTT LABORATORIES, INC.
TABLE 316 ABBOTT LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 47 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
12.1.6 ALMAC GROUP
TABLE 317 ALMAC GROUP: BUSINESS OVERVIEW
12.1.7 DANAHER CORPORATION
TABLE 318 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
12.1.8 ILLUMINA, INC.
TABLE 319 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 49 ILLUMINA, INC.: COMPANY SNAPSHOT (2020)
12.1.9 BIOMÉRIEUX SA
TABLE 320 BIOMÉRIEUX SA: BUSINESS OVERVIEW
FIGURE 50 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020)
12.1.10 MYRIAD GENETICS, INC.
TABLE 321 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
FIGURE 51 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2020)
12.1.11 SYSMEX CORPORATION
TABLE 322 SYSMEX CORPORATION: BUSINESS OVERVIEW
FIGURE 52 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020)
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS
12.2.1 ABNOVA CORPORATION
12.2.2 GUARDANT HEALTH, INC.
12.2.3 ICON PLC
12.2.4 BIOGENEX LABORATORIES, INC.
12.2.5 INVIVOSCRIBE TECHNOLOGIES
12.2.6 ARCHERDX, INC.
12.2.7 NG BIOTECH
12.2.8 Q? SOLUTIONS
12.2.9 AMOY DIAGNOSTICS CO., LTD.
12.2.10 ABACUS DIAGNOSTICA OY
12.2.11 ASURAGEN INC.
12.2.12 SAGA DIAGNOSTICS
12.2.13 MESO SCALE DIAGNOSTICS, LLC.
12.2.14 CREATIVE BIOLABS

13 APPENDIX (Page No. - 323)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS